Why the study?
Does low-dose daunorubicin induction treatment cause late cardiac damage in childhood acute lymphoblastic leukemia survivors?
Population
90 event-free survivors of childhood acute lymphoblastic leukemia, median age at diagnosis 4.5 years…
Comparison
Daunorubicin 25 mg/m2 i.v. weekly for 4 weeks… vs Induction treatment without daunorubicin.
Design
RCT, Patients were randomized to receive or not to receive daunorubicin during…
Follow-up
median 14.8 years (range 11.4-17.8 years)
Authors
Loading...
Low-dose daunorubicin induction is safe for late cardiac function in childhood ALL survivors; confirms no damage versus controls at 100 mg/m² cumulative dose.
Does low-dose daunorubicin induction treatment cause late cardiac damage in childhood acute lymphoblastic leukemia survivors?
Low-dose daunorubicin (cumulative dose 100 mg/m2) during induction treatment for childhood ALL appears safe and does not cause long-term cardiac damage.
Rammeloo et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: